With plans to bring su­r­u­fa­tinib state­side, Chi-Med vast­ly scales up man­u­fac­tur­ing with new Chi­nese plant

Hutchi­son Chi­na MediTech, or Chi-Med, is at­tempt­ing to break new ground by bring­ing its in­ter­nal­ly de­vel­oped on­col­o­gy can­di­date su­r­u­fa­tinib to US shores—which would make it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER